Vicebio Acquired by Sanofi for $1.6 Billion in Strategic BioPharma Move

Vicebio Ltd, a biopharmaceutical entity engaged in pioneering vaccine development against critical respiratory viral infections, has agreed to be acquired by Sanofi. This strategic acquisition involves an upfront cash transfer of US$1.15 billion with conditional milestone payments culminating in a US$1.6 billion total. Vicebio, a creation of the healthcare-focused investment firm Medicxi Ventures, employs unique Molecular Clamp technology derived from The University of Queensland to foster novel vaccine design, notably encompassing its lead asset, VXB-241, currently in Phase 1 trials targeting RSV and hMPV. While the acquisition incorporates the significant expertise and resource capacity of Sanofi, Vicebio's technology holds expansive potential for addressing numerous viral pathogens including influenza and coronaviruses. Medicxi has been instrumental in Vicebio's growth, both in ideation and capital financing during its Series B round, aligning high-profile collaborators like TCGX and Goldman Sachs Alternatives. The transaction underscores Sanofi's commitment to expanding its R&D arsenal with AI-driven immunotherapy solutions.